Drugs that contain Viloxazine Hydrochloride

1. List of Qelbree drug patents

QELBREE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(6 years from now)

US11458143 SUPERNUS PHARMS NA
Sep, 2029

(6 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(9 years from now)

US9358204 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(9 years from now)

US9662338 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 2, 2026
New Patient Population (NPP) Apr 29, 2025

NCE-1 date: 2025-04-02

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); U-727: for the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

QELBREE family patents

14

United States

4

Australia

3

Japan

2

Canada

2

European Union

1

Mexico

1

Spain

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in